Different Anti-Spastic Therapy Strategies After CABG Using Radial Artery Grafts
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The Pilot study will be a single-center, randomized, open-label, active-controlled trial.
After CABG surgery using Radial Artery Grafts (RA-CABG) and signing the informed consent, all
patients will be screened according to the inclusion and exclusion criteria. Estimated 150
patients will be enrolled and randomized by ratio 1:1:1 to receive either Nicorandil (5mg tid
po) or Diltiazem (180mg qd po) or Isosorbide Mononitrate (50mg qd po). Follow-up visits will
be conducted at Day 7, 28, 84, 168 after surgery. The last evaluation of study endpoints and
other adverse events will be at Day 168.
The pilot study is designed to explore the angiography outcomes of grafts and cardiovascular
outcomes of patients, as well as safety outcomes among different anti-spastic regimens after
RA-CABG.